Five Firms Report Mixed September-Quarter Results

Companies reported mixed financial results for periods ending September 30, 2026. Vycor Medical’s revenue declined 18% in the quarter and 11% over nine months, while operating profit rose for the nine-month period but fell in the quarter; the company cited unusually strong U.S. sales in 2025 as a major factor in the comparisons. Global Vectra Helicorp’s second-quarter revenue fell year over year and its net loss widened to INR 264.78 million. Venlon Enterprises reported sharply lower sales and revenue, although its quarterly and six-month losses narrowed. By contrast, Narmada Gelatines increased quarterly and six-month revenue and net income, while Venmax Drugs and Pharmaceuticals recorded substantial growth in revenue and net income over both periods.